Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Accounts Payables (2018 - 2025)

Historic Accounts Payables for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $375380.0.

  • BioNexus Gene Lab's Accounts Payables fell 6366.56% to $375380.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $375380.0, marking a year-over-year decrease of 6366.56%. This contributed to the annual value of $1.5 million for FY2024, which is 721.35% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported Accounts Payables of $375380.0 as of Q3 2025, which was down 6366.56% from $1.4 million recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Accounts Payables high stood at $2.0 million for Q4 2021, and its period low was $34884.0 during Q2 2021.
  • In the last 5 years, BioNexus Gene Lab's Accounts Payables had a median value of $1.4 million in 2023 and averaged $1.2 million.
  • In the last 5 years, BioNexus Gene Lab's Accounts Payables soared by 469315.9% in 2022 and then tumbled by 6366.56% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Accounts Payables stood at $2.0 million in 2021, then decreased by 7.52% to $1.9 million in 2022, then fell by 24.66% to $1.4 million in 2023, then rose by 7.21% to $1.5 million in 2024, then crashed by 75.03% to $375380.0 in 2025.
  • Its Accounts Payables was $375380.0 in Q3 2025, compared to $1.4 million in Q2 2025 and $1.2 million in Q1 2025.